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Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer-related deaths among both men and women in
the United States and remains essentially without effective ther-
apies. The 5-year survival of patients with pancreatic cancer is a
dismal 6% or less. Environmental risk factors such as smoking,
diabetes, obesity, and alcoholism play major roles in the promo-
tion of PDAC. However, currently we have limited understanding
of how these risk factors promote the disease. The papers pre-
sented in this topic illustrate the latest knowledge regarding the
mechanisms of pancreatic cancer induction and promotion by
major risk factors such as smoking, pancreatitis, alcohol abuse,
obesity and diabetes (Kolodecik et al., 2013), and less studied fac-
tors such blood group types (Pelzer et al., 2013) and the genetic
mutations (Kong et al., 2013; Reznik et al., 2014; Weiss, 2014).
Indeed, an inherited predisposition to PDAC is believed to
present in familial cancer syndromes such as the Peutz-Jeghers
Syndrome, which is associated with germline mutations in the
STK11/LKB1 gene, Familial Atypical Multiple Mole Melanoma
syndrome, which results due to germline mutations in the
p16/CDKN2A gene, Hereditary Breast-Ovarian Cancer syndrome
(BRCA1/2 genes), Hereditary Non-polyposis Colorectal Cancer
(mismatch repair genes), and Familial Adenomatous Polyposis
syndrome (Reznik et al., 2014). Hereditary causes of pancreati-
tis, such as the autosomal dominant form caused by germline
mutations of the cationic trypsinogen gene, PRSS1, have been
indirectly linked to PDAC through early onset chronic pancre-
atitis with an associated 53-fold increased incidence and approx-
imately 40% of hereditary pancreatitis patients noted to develop
pancreatic cancer by age 70 (Weiss, 2014). Finally, more patients
with blood group A suffer from PDAC whereas blood group O
was less frequent in patients with PDAC (Pelzer et al., 2013). Kras
mutations remain the most abundant genetic alteration found in
pancreatic cancer patients. Kras mutations may lead to reducing
power for ROS detoxification, leading to low ROS levels in pan-
creatic pre-neoplastic cells and in cancer cells. In adult stem cells
and cancer stem cells, low ROS levels have been associated with
the formation of a proliferation-permissive intracellular environ-
ment and with perseverance of self-renewal capacities. Therefore,
it is conceivable that low intracellular ROS levels may contribute
significantly to oncogenic Kras-mediated PDAC formation (Kong
et al., 2013).
Specific gene-based, gene-product, and marker-based testing
for the early detection of pancreatic cancer are currently being
developed, with the potential for these to be useful as potential
therapeutic targets as well.
Today, the role of stromal cells is highly appreciated for pancre-
atic cancer development. Immune cell infiltration into the tumor
not only fail to contribute to disease eradication but rather due to
exhibiting a Th2-type inflammation and immunosuppression is
associated with more rapid disease progression, cachexia induc-
tion, and reduced survival. Polarization of macrophages toward
M2-type correlates with a poor prognosis after surgery in resected
patients. High CD163+ and CD204+ cell counts correlate with
metastasis and poor prognosis in PDAC patients (Protti and De
Monte, 2013; Tan et al., 2014).
Src kinase might serve as a critical mechanistic link between
inflammation and cancer, mediating and propagating a cycle
between immune and tissue cells that can ultimately lead to the
development and progression of cancer (Liu et al., 2013). In addi-
tion, there is now compelling evidence that pancreatic stellate
cells interact not only with cancer cells themselves, but with sev-
eral other cell types in the stroma (endothelial cells, immune
cells, and possibly neuronal cells) to promote cancer progres-
sion. Strategies to target the tumor microenvironment cells are
proposed (Wilson et al., 2014). The central role of the mam-
malian target of rapamycin (mTOR) in mediating a crosstalk
between the insulin/IGF-1 and GPCR signaling in pancreatic can-
cer cells is discussed in depth and strategies, including the use of
metformin, to target this signaling pathway in PDAC cells are pro-
posed (Rozengurt, 2014). Finally, a comprehensive review of the
latest animalmodels of pancreatic cancer are discussed, proposing
novel tools to study the mechanism of pancreatic cancer initiation
and promotion by major risk factors.
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